Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor 
panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with 
idiopathic pulmonary fibrosis

Korfei, Martina; Stelmaszek, Daniel; MacKenzie, BreAnne; Skwarna, Sylwia; Chillappagari, Shashipavan; Bach, Anna C.; Ruppert, Clemens; Saito, Shigeki; Mahavadi, Poornima; Klepetko, Walter; Fink, Ludger; Seeger, Werner; Lasky, Joseph A.; Pullamsetti, Soni S.; Kraemer, Oliver H.; Guenther, Andreas

doi:10.1371/journal.pone.0207915

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis

MPS-Authors

/persons/resource/persons224334

Seeger, Werner
Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Max Planck Society;

/persons/resource/persons224324

Pullamsetti, Soni S.
Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Korfei, M., Stelmaszek, D., MacKenzie, B., Skwarna, S., Chillappagari, S., Bach, A. C., et al. (2018). Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLOS ONE, 13(11): e0207915. doi:10.1371/journal.pone.0207915.

Cite as: https://hdl.handle.net/21.11116/0000-0004-5F46-4

Abstract

There is no abstract available